Phase 3 trial finds adding durvalumab during chemoradiation does not improve overall survival compared with standard consolidation therapy alone.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/concurrent-durvalumab-shows-no-survival-benefit-nsclc-2025a1000nxs?src=rss
Author :
Publish date : 2025-09-10 14:17:00
Copyright for syndicated content belongs to the linked Source.
